Tumor necrosis factor as a therapeutic target of rheumatologic disease
- 26 October 2007
- journal article
- review article
- Published by Taylor & Francis in Emerging Therapeutic Targets
- Vol. 11 (11), 1369-1384
- https://doi.org/10.1517/14728222.11.11.1369
Abstract
TNF-alpha is a crucial pro-inflammatory and immunoregulatory cytokine that is central to the pathogenesis of various inflammatory and autoimmune conditions. A number of controlled trials have shown effectiveness for TNF-alpha inhibitors in several diseases, in particular rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and Crohn's disease. These agents may also be useful in additional autoimmune conditions. The introduction of TNF-alpha inhibitors has revolutionized the therapeutic approach and treatment paradigms especially for patients with rheumatoid arthritis. Despite extensive investigation, the full profile of their mechanisms of action remain incompletely understood. Optimal use of these agents requires consideration of their possible adverse effects. In addition to the presently available TNF-alpha blockers, other agents targeting this key mediator are under study. Recent advances and future directions in anti-TNF-alpha therapy are discussed in this paper.Keywords
This publication has 100 references indexed in Scilit:
- Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo‐controlled trialArthritis Care & Research, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Plenary Session [OP25–OP30]Rheumatology, 2006
- Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritisRheumatology, 2005
- Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapyArthritis & Rheumatism, 2005
- Epidemiology of psoriatic arthritis in the population of the United StatesJournal of the American Academy of Dermatology, 2005
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACHInternational Journal of Cardiology, 2002
- Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activationAnnals Of The Rheumatic Diseases, 2002
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980